Telix Pharmaceuticals (innovations) Pty Limited

This Phase 3 trial tests whether adding a targeted radiation drug (lutetium-177 rosopatamab) to standard care can help men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The study will enroll 520 men across multiple countries. Par…

This study tests a new drug, TLX101-Tx, that delivers radiation directly to glioblastoma cells. It is combined with standard chemotherapy (lomustine) and compared to chemotherapy alone in 50 adults whose brain cancer has returned after initial treatment. The goal is to see if the…

This phase 3 trial tests a drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for adults with advanced clear cell kidney cancer that has returned or spread after prior treatments. The study first finds the best dose, then compares it to stan…

This early-phase trial is testing a radioactive drug called 131I-TLX101, given alongside standard care, for people newly diagnosed with glioblastoma, an aggressive brain cancer. The study involves 12 participants and aims to find the safest dose and check for side effects. It is …

This Phase 3 trial is testing whether combining a special PET scan (PSMA PET) with MRI can detect prostate cancer better than standard methods. About 204 men with suspected prostate cancer will receive the combined imaging, and results will be compared to biopsy findings. The goa…

This early-phase study tests a single dose of TLX090-Tx, a radioactive drug, in 33 adults with advanced cancer that has spread to the bones and causes pain. The goal is to find a safe dose and see if it can reduce pain. Participants must have at least one painful bone spot and ha…